Cardiolipin remodeling by ALCAT1 links hypoxia to coronary artery disease by promoting mitochondrial dysfunction

Area of Science:

• Mitochondrial biology
• Cardiovascular research
• Molecular medicine

Background:

• Cardiolipin is crucial for cardiac health, with tetralinoleoyl cardiolipin (TLCL) depletion linked to coronary heart disease (CHD) pathogenesis.
• The mechanisms connecting hypoxia to TLCL loss and subsequent cardiac dysfunction in CHD remain poorly understood.

Purpose of the Study:

• To identify the molecular link between myocardial infarction-induced hypoxia and cardiac pathogenesis.
• To investigate the role of acyl-coenzyme A:lysocardiolipin acyltransferase-1 (ALCAT1) in cardiolipin remodeling and its impact on heart health.

Main Methods:

• Utilized an animal model of myocardial infarction (MI) to study ALCAT1 expression and function.
• Investigated the effects of ALCAT1 gene ablation and pharmacological inhibition (using Dafaglitapin) on cardiolipin levels, mitochondrial function, and CHD markers.
• Analyzed the involvement of hypoxia-inducible factor 1α (HIF-1α) signaling pathways.

Main Results:

• ALCAT1 expression was significantly upregulated by MI, correlating with myocardial hypoxia, oxidative stress, TLCL depletion, and mitochondrial dysfunction.
• ALCAT1 inhibition (genetic or pharmacological) restored TLCL levels and improved mitochondrial respiration by attenuating HIF-1α signaling.
• ALCAT1 inhibition effectively reduced CHD progression, including dilated cardiomyopathy, left ventricle dysfunction, inflammation, fibrosis, and apoptosis.

Conclusions:

• ALCAT1 acts as a critical mediator linking myocardial hypoxia to cardiolipin remodeling and mitochondrial dysfunction in CHD.
• Targeting ALCAT1 with inhibitors like Dafaglitapin represents a promising therapeutic strategy for treating coronary heart disease.